1. The role of oxaliplatin in the adjuvant setting of different Lauren’s type of gastric adenocarcinoma after D2 gastrectomy: a real-world study
    Xi Cheng et al, 2019, Gastric Cancer CrossRef

  2. Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients


    Shan Yu et al, 2020, Cancer Management and Research CrossRef
  3. Survival Advantages in Gastric Cancer Patients Receiving Preoperative SOX Regimen Chemotherapy
    Qian Zhang et al, 2023, Cancer Biotherapy and Radiopharmaceuticals CrossRef
  4. Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis
    Chih-Chieh Yen et al, 2021, BMC Cancer CrossRef
  5. Efficacy and safety of SOX chemotherapy with or without surgery in AFP-producing advanced gastric cancer
    Zhu Li et al, 2017, Oncology Letters CrossRef
  6. CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients
    Lin Yang et al, 2017, Genomics, Proteomics & Bioinformatics CrossRef
  7. Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer
    Guoxiu Wang et al, 2018, BMC Cancer CrossRef
  8. Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients
    Xichao Dai et al, 2017, Oncotarget CrossRef